PL3470418T3 - Przeciwciało znakowane izotopem promieniotwórczym specyficzne dla danego miejsca wykorzystujące peptyd wiążący IgG - Google Patents
Przeciwciało znakowane izotopem promieniotwórczym specyficzne dla danego miejsca wykorzystujące peptyd wiążący IgGInfo
- Publication number
- PL3470418T3 PL3470418T3 PL17813244.5T PL17813244T PL3470418T3 PL 3470418 T3 PL3470418 T3 PL 3470418T3 PL 17813244 T PL17813244 T PL 17813244T PL 3470418 T3 PL3470418 T3 PL 3470418T3
- Authority
- PL
- Poland
- Prior art keywords
- igg
- site
- binding peptide
- radiolabeled antibody
- specific radiolabeled
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
- A61K51/1051—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from breast, e.g. the antibody being herceptin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/64—Cyclic peptides containing only normal peptide links
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
- G01N33/532—Production of labelled immunochemicals
- G01N33/534—Production of labelled immunochemicals with radioactive label
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2123/00—Preparations for testing in vivo
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Oncology (AREA)
- Public Health (AREA)
- Optics & Photonics (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2016117395 | 2016-06-13 | ||
| JP2016227025 | 2016-11-22 | ||
| PCT/JP2017/021558 WO2017217347A1 (ja) | 2016-06-13 | 2017-06-12 | ＩｇＧ結合ペプチドによる部位特異的ＲＩ標識抗体 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3470418T3 true PL3470418T3 (pl) | 2024-12-16 |
Family
ID=60663283
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL17813244.5T PL3470418T3 (pl) | 2016-06-13 | 2017-06-12 | Przeciwciało znakowane izotopem promieniotwórczym specyficzne dla danego miejsca wykorzystujące peptyd wiążący IgG |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US12037417B2 (pl) |
| EP (1) | EP3470418B1 (pl) |
| JP (2) | JP6959616B2 (pl) |
| KR (2) | KR102741325B1 (pl) |
| CN (1) | CN109071606A (pl) |
| CA (1) | CA3026520A1 (pl) |
| DK (1) | DK3470418T3 (pl) |
| ES (1) | ES2985878T3 (pl) |
| FI (1) | FI3470418T3 (pl) |
| PL (1) | PL3470418T3 (pl) |
| SG (2) | SG11201810923YA (pl) |
| TW (1) | TWI837077B (pl) |
| WO (1) | WO2017217347A1 (pl) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3299383B1 (en) * | 2015-05-20 | 2025-12-03 | Kagoshima University | Specific modification of antibody with igg-binding peptide |
| AU2018259856B2 (en) | 2017-04-28 | 2025-05-01 | Ajinomoto Co., Inc. | Compound having substance that has affinity for soluble protein, cleavable moiety, and reactive group, or salt thereof |
| WO2018230257A1 (ja) * | 2017-06-16 | 2018-12-20 | 国立大学法人鹿児島大学 | ＩｇＧ結合ペプチド、及び該ペプチドによる抗体の特異的修飾 |
| TW202003556A (zh) | 2018-04-16 | 2020-01-16 | 日商日本醫事物理股份有限公司 | 改性抗體及放射性金屬標示抗體 |
| KR20210020901A (ko) * | 2018-06-14 | 2021-02-24 | 아지노모토 가부시키가이샤 | 항체에 대한 친화성 물질, 절단성 부분 및 반응성기를 갖는 화합물 또는 이의 염 |
| KR102880460B1 (ko) * | 2018-06-14 | 2025-11-06 | 아지노모토 가부시키가이샤 | 항체에 대한 친화성 물질 및 생체 직교성 관능기를 갖는 화합물 또는 이의 염 |
| JPWO2020090979A1 (ja) * | 2018-10-31 | 2021-09-24 | 味の素株式会社 | 抗体に対する親和性物質、切断性部分および反応性基を有する化合物またはその塩 |
| CN110007019A (zh) * | 2019-03-29 | 2019-07-12 | 绿城农科检测技术有限公司 | 一种同时定量检测母乳中三种抗体含量的方法 |
| JP7356677B2 (ja) * | 2019-05-22 | 2023-10-05 | 学校法人東京薬科大学 | 複合体 |
| BR112022007240A2 (pt) | 2019-10-18 | 2022-07-05 | Nihon Mediphysics Co Ltd | Método para produzir um anticorpo marcado com metal radioativo, anticorpo marcado com metal radioativo, conector de quelato, e, anticorpo modificado com peptídeo |
| IL292133A (en) * | 2019-10-18 | 2022-06-01 | Nihon Mediphysics Co Ltd | Ri-labeled humanized antibody |
| AU2020396219A1 (en) * | 2019-12-03 | 2022-07-14 | Debiopharm Research & Manufacturing S.A. | Reactive conjugates |
| WO2022078566A1 (en) * | 2020-10-12 | 2022-04-21 | Debiopharm Research & Manufacturing S.A. | Reactive conjugates |
| MX2023004428A (es) * | 2020-10-16 | 2023-05-04 | Nihon Mediphysics Co Ltd | Complejos radioactivos de anticuerpo anti-her2 y radiofarmaceutico. |
| AU2021364978A1 (en) | 2020-10-22 | 2023-06-15 | Nihon Medi-Physics Co., Ltd. | Method for producing radioactive zirconium complex |
| JP7154465B1 (ja) | 2021-01-08 | 2022-10-17 | 日本メジフィジックス株式会社 | Ａｃ－２２５溶液の製造方法およびＡｃ－２２５溶液を用いた医薬の製造方法 |
| WO2022196675A1 (ja) | 2021-03-16 | 2022-09-22 | 味の素株式会社 | 複合体またはその塩、およびその製造方法 |
| TW202304522A (zh) | 2021-03-31 | 2023-02-01 | 日商日本醫事物理股份有限公司 | 抗ｅｇｆｒ抗體之放射性複合體，及放射性醫藥 |
| US20240207464A1 (en) | 2021-04-20 | 2024-06-27 | Nihon Medi-Physics Co., Ltd. | Radioactive complex of anti-cd20 antibody, and radiopharmaceutical |
| TW202308698A (zh) | 2021-04-21 | 2023-03-01 | 日商日本醫事物理股份有限公司 | 經放出β射線之核種標記之人源化抗體 |
| EP4327833A1 (en) | 2021-04-21 | 2024-02-28 | Nihon Medi-Physics Co., Ltd. | Radioactive antitumor agent |
| WO2023277144A1 (ja) * | 2021-06-30 | 2023-01-05 | 日本メジフィジックス株式会社 | Ｈｅｇ１タンパク質に結合するヒト化抗体および当該抗体と放射性核種との複合体 |
| TW202325343A (zh) | 2021-08-31 | 2023-07-01 | 日商日本醫事物理股份有限公司 | 去醣基化抗體之放射性複合體，及放射性醫藥 |
| JPWO2023038082A1 (pl) | 2021-09-08 | 2023-03-16 | ||
| TW202400240A (zh) | 2022-02-15 | 2024-01-01 | 日商日本醫事物理股份有限公司 | 抗ｖｅｇｆ抗體的放射性複合體及放射性醫藥 |
| JPWO2023171809A1 (pl) * | 2022-03-11 | 2023-09-14 | ||
| JPWO2023190402A1 (pl) | 2022-03-30 | 2023-10-05 | ||
| AU2023367497A1 (en) | 2022-10-26 | 2025-05-15 | Nihon Medi-Physics Co., Ltd. | Radioactive pharmaceutical composition |
| EP4609878A1 (en) | 2022-10-26 | 2025-09-03 | Nihon Medi-Physics Co., Ltd. | Method for producing radioactive pharmaceutical composition |
| JPWO2024190896A1 (pl) | 2023-03-15 | 2024-09-19 | ||
| CN117466980A (zh) * | 2023-11-02 | 2024-01-30 | 浙江普罗亭健康科技有限公司 | 基于多肽链骨架应用于金属抗体标记的负载金属缀合物及其应用 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2604092B1 (fr) * | 1986-09-19 | 1990-04-13 | Immunotech Sa | Immunoreactifs destines a cibler les cellules animales pour leur visualisation ou leur destruction in vivo |
| US5849261A (en) * | 1991-02-08 | 1998-12-15 | Diatide, Inc. | Radiolabeled vasoactive intestinal peptides for diagnosis and therapy |
| US6962702B2 (en) * | 1998-06-22 | 2005-11-08 | Immunomedics Inc. | Production and use of novel peptide-based agents for use with bi-specific antibodies |
| EP1089766B1 (en) | 1998-06-22 | 2010-03-17 | Immunomedics, Inc. | Use of bi-specific antibodies for pre-targeting diagnosis and therapy |
| EP1757701A1 (en) | 1999-12-24 | 2007-02-28 | Genentech, Inc. | Methods and compositions for prolonging elimination half-times of bioactive compounds |
| WO2003048207A2 (en) * | 2001-11-28 | 2003-06-12 | Immunomedics, Inc. | Anti-dota antibody |
| CA2487692A1 (en) * | 2002-05-29 | 2003-12-11 | Immunomedics, Inc. | Methods and compositions for radioimmunotherapy of brain and cns tumors |
| US8372950B2 (en) | 2006-11-02 | 2013-02-12 | Kagoshima University | IgG binding peptide |
| CN102159231B (zh) | 2008-07-18 | 2016-06-15 | 三一治疗公司 | 治疗免疫介导的登革热感染和登革热感染(包括登革出血热和登革休克综合征)的抗体依赖性增强作用的方法 |
| EP2383336A4 (en) | 2009-01-23 | 2013-01-23 | Mmt Co Ltd | PEPTIDE CAPABLE OF BINDING TO AN IMMUNOGLOBULIN |
| US9593147B2 (en) | 2010-05-24 | 2017-03-14 | Kagoshima University | IgA-binding peptide and purification of IgA using the same |
| EP2749646B1 (en) * | 2011-08-24 | 2018-03-21 | Kagoshima University | IgG-BINDING PEPTIDE AND METHOD FOR DETECTING AND PURIFYING IgG USING SAME |
| EP3299383B1 (en) * | 2015-05-20 | 2025-12-03 | Kagoshima University | Specific modification of antibody with igg-binding peptide |
| US11186613B2 (en) | 2016-11-18 | 2021-11-30 | Kagoshima University | Solid-phase support comprising IgG-binding peptide, and method for separating IgG |
-
2017
- 2017-06-12 PL PL17813244.5T patent/PL3470418T3/pl unknown
- 2017-06-12 DK DK17813244.5T patent/DK3470418T3/da active
- 2017-06-12 KR KR1020237005091A patent/KR102741325B1/ko active Active
- 2017-06-12 KR KR1020187035255A patent/KR20190018423A/ko not_active Ceased
- 2017-06-12 US US16/309,272 patent/US12037417B2/en active Active
- 2017-06-12 SG SG11201810923YA patent/SG11201810923YA/en unknown
- 2017-06-12 FI FIEP17813244.5T patent/FI3470418T3/fi active
- 2017-06-12 EP EP17813244.5A patent/EP3470418B1/en active Active
- 2017-06-12 CN CN201780025871.0A patent/CN109071606A/zh active Pending
- 2017-06-12 JP JP2018523879A patent/JP6959616B2/ja active Active
- 2017-06-12 TW TW106119410A patent/TWI837077B/zh active
- 2017-06-12 SG SG10202012408UA patent/SG10202012408UA/en unknown
- 2017-06-12 CA CA3026520A patent/CA3026520A1/en active Pending
- 2017-06-12 ES ES17813244T patent/ES2985878T3/es active Active
- 2017-06-12 WO PCT/JP2017/021558 patent/WO2017217347A1/ja not_active Ceased
-
2021
- 2021-09-30 JP JP2021160840A patent/JP7165366B2/ja active Active
-
2024
- 2024-07-15 US US18/773,104 patent/US20240368223A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2022008678A (ja) | 2022-01-13 |
| EP3470418B1 (en) | 2024-07-31 |
| CA3026520A1 (en) | 2017-12-21 |
| CN109071606A (zh) | 2018-12-21 |
| US20200181196A1 (en) | 2020-06-11 |
| TW201802108A (zh) | 2018-01-16 |
| SG11201810923YA (en) | 2019-01-30 |
| DK3470418T3 (da) | 2024-09-30 |
| ES2985878T3 (es) | 2024-11-07 |
| KR20190018423A (ko) | 2019-02-22 |
| JP7165366B2 (ja) | 2022-11-04 |
| FI3470418T3 (fi) | 2024-09-17 |
| EP3470418A4 (en) | 2019-12-11 |
| JPWO2017217347A1 (ja) | 2019-05-09 |
| US12037417B2 (en) | 2024-07-16 |
| KR20230027320A (ko) | 2023-02-27 |
| JP6959616B2 (ja) | 2021-11-02 |
| SG10202012408UA (en) | 2021-01-28 |
| WO2017217347A1 (ja) | 2017-12-21 |
| EP3470418A1 (en) | 2019-04-17 |
| KR102741325B1 (ko) | 2024-12-10 |
| TWI837077B (zh) | 2024-04-01 |
| US20240368223A1 (en) | 2024-11-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL3470418T3 (pl) | Przeciwciało znakowane izotopem promieniotwórczym specyficzne dla danego miejsca wykorzystujące peptyd wiążący IgG | |
| IL268620A (en) | Anti-lag3 antibodies | |
| IL259643A (en) | Antibodies and antibody fragments for site-specific conjugation | |
| IL263509B (en) | Anti-pd-l1 antibodies and uses thereof | |
| DK3455257T3 (da) | Anti-pd-l1-antistoffer | |
| IL263452A (en) | Anti-ige antibodies | |
| LT3558390T (lt) | Amanitino ir antikūnų konjugatai | |
| IL268667A (en) | Radiolabeled anti-lag3 antibodies for immuno-pet imaging | |
| DK3411404T3 (da) | Psma- og cd3-bispecifikke t-celleinddragende antistofkonstruktioner | |
| EP3426686C0 (en) | Humanized Anti-PACAP Antibodies and Their Uses | |
| EP3498840A4 (en) | ANTI-LAG-3 ANTIBODIES | |
| DK3458479T3 (da) | Anti-b7-h3-antistoffer og antistof-lægemiddelkonjugater | |
| PL3436079T3 (pl) | Antygen chimeryczny i receptory komórek t oraz sposoby ich stosowania | |
| EP3481869A4 (en) | ANTI-CD73 ANTIBODIES | |
| DK3468990T3 (da) | Anti-C5-antistoffer og anvendelser deraf | |
| EP3532489A4 (en) | ANTI-TL1A NEUTRALIZING MONOCLONAL ANTIBODIES | |
| EP3589648A4 (en) | MONOCLONAL ANTI-RSV ANTIBODY FORMULATION | |
| DK3441086T3 (da) | Monoklonalt anti-PD-1-antistof | |
| DK3642227T3 (da) | Hundeantistofbiblioteker | |
| EP3580239A4 (en) | ANTIBODY ANTI-ILT3 AND ANTIBODY-DRUG CONJUGATES | |
| EP3442576A4 (en) | HIGH AFFINITY B7-H6 ANTIBODIES AND ANTIBODY FRAGMENTS | |
| LT3561057T (lt) | Anti-cd3 antikūnas ir molekulė, kurios sudėtyje yra minėtas antikūnas | |
| PL3402821T3 (pl) | Przeciwciało wiążące psma i jego zastosowania | |
| DK3452513T3 (da) | Humaniserede anti-il-ir3-antistoffer | |
| EP3612567A4 (en) | ANTI-BODY-VTCN1 ANTIBODIES AND ANTI-BODY-DRUG CONJUGATES |